Bagsværd, Hovedstaden, Denmark The main department of described VC is located in the Bagsvu00e6rd. The company was established in Europe in Denmark. Novo Ventures appeared to be a CVC structure as part of the corporation.
Among the most popular portfolio startups of the fund, we may highlight Spectranetics, Alios BioPharma, Cianna Medical. The fund has exact preference in some founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Pharmaceutical, Genetics. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Novo Ventures, startups are often financed by Novartis Venture Fund, Novo Holdings, TPG Biotech. The meaningful sponsors for the fund in investment in the same round are TPG Biotech, New Enterprise Associates, Versant Ventures. In the next rounds fund is usually obtained by Novo Holdings, SV Health Investors, TPG Biotech.
Besides them, we counted 7 critical employees of this fund in our database.
The important activity for fund was in 2015. Despite it in 2019 the fund had an activity. Comparing to the other companies, this Novo Ventures performs on 16 percentage points more the average number of lead investments. Considering the real fund results, this VC is 16 percentage points more often commits exit comparing to other organizations. The fund is constantly included in 2-6 deals per year. The increased amount of exits for fund were in 2014. Deals in the range of 10 - 50 millions dollars are the general things for fund.
Related Funds
| Fund Name | Location |
| Bandai Namco Entertainment | Chiyoda, Japan |
| Century Financial Partners | - |
| Chun Yang Investment Management | China, Shanghai |
| Dundee Goodman Merchant Partners | Canada, Ontario, Toronto |
| Everbright Prestige Capital | Beijing, Beijing, China |
| ProQuest Investments | New Jersey, Princeton, United States |
| Suffolk Capital | - |
| Thunder Bay Ventures | Canada, Ontario, Thunder Bay |
Discover 5 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Amolyt Pharma | $153M | 06 Jan 2023 | Écully, Rhone-Alpes, France | ||
Theraxyte | $10M | 11 Jul 2022 | Changping, Beijing, China | ||
Amolyt Pharma | $80M | 16 Sep 2021 | Écully, Rhone-Alpes, France | ||
Reneo Pharmaceuticals | $95M | 09 Dec 2020 | San Diego, California, United States | ||
Lava Therapeutics | $83M | 17 Sep 2020 | Utrecht, Utrecht, Netherlands | ||
NodThera | $55M | 03 Jun 2020 | Uttlesford, England, United Kingdom | ||
Anokion | $40M | 11 Sep 2019 | Vaud, Switzerland | ||
Alizé Pharma | $79M | 31 Jul 2019 | France, Auvergne-Rhône-Alpes, France | ||
Galera Therapeutics | $70M | 19 Sep 2018 | Pennsylvania, United States |
– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.
– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Amolyt Pharma | $153M | 06 Jan 2023 | Écully, Rhone-Alpes, France | ||
Theraxyte | $10M | 11 Jul 2022 | Changping, Beijing, China | ||
Amolyt Pharma | $80M | 16 Sep 2021 | Écully, Rhone-Alpes, France | ||
Reneo Pharmaceuticals | $95M | 09 Dec 2020 | San Diego, California, United States | ||
Lava Therapeutics | $83M | 17 Sep 2020 | Utrecht, Utrecht, Netherlands | ||
NodThera | $55M | 03 Jun 2020 | Uttlesford, England, United Kingdom | ||
Anokion | $40M | 11 Sep 2019 | Vaud, Switzerland | ||
Alizé Pharma | $79M | 31 Jul 2019 | France, Auvergne-Rhône-Alpes, France | ||
Galera Therapeutics | $70M | 19 Sep 2018 | Pennsylvania, United States |
